Stoke Therapeutics, Inc. (STOK) Operating Income (Loss) USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Stoke Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2018 to 2024.
  • Stoke Therapeutics, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$28.4 M, a 14.9% decline year-over-year.
  • Stoke Therapeutics, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$118 M, a 13.6% decline year-over-year.
  • Stoke Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$115 M, a 9.98% decline from 2022.
  • Stoke Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$104 M, a 21.3% decline from 2021.
  • Stoke Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$86.1 M, a 62.3% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$118 M -$28.4 M -$3.68 M -14.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 -$115 M -$29.6 M -$2.41 M -8.88% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-25
Q3 2023 -$112 M -$27.2 M -$86 K -0.32% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$112 M -$33.3 M -$8.02 M -31.8% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-07
Q1 2023 -$104 M -$24.7 M +$105 K +0.42% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 -$104 M -$27.2 M -$2.65 M -10.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-25
Q3 2022 -$102 M -$27.1 M -$4.47 M -19.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$97.2 M -$25.2 M -$3.21 M -14.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 -$94 M -$24.8 M -$7.97 M -47.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$86.1 M -$24.5 M -$9.94 M -68.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 -$76.1 M -$22.7 M -$8.97 M -65.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$67.2 M -$22 M -$9.02 M -69.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$58.1 M -$16.8 M -$5.09 M -43.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$53 M -$14.6 M -$3.52 M -31.8% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-09
Q3 2020 -$49.5 M -$13.7 M -$3.87 M -39.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$45.7 M -$13 M -$4.57 M -54.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 -$41.1 M -$11.7 M -$5.41 M -85.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$35.7 M -$11.1 M -$6.53 M -144% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 -$29.2 M -$9.84 M -$6.53 M -197% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-09
Q2 2019 -$22.6 M -$8.45 M -$5.44 M -181% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-09
Q1 2019 -$17.2 M -$6.32 M -$4.41 M -231% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-09
Q4 2018 -$12.8 M -$4.54 M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-23
Q3 2018 -$3.32 M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-23
Q2 2018 -$3.01 M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-23
Q1 2018 -$1.91 M Jan 1, 2018 Mar 31, 2018 10-K 2020-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.